Sucrosomial® Iron Featured in the World Health Organization Guidelines

PharmaNutra’s patent is recognized by the WHO as the only oral iron supplement recommended for treating iron deficiency anemia in patients with cardiovascular diseases and diabetes.

PharmaNutra is proud to announce that Sucrosomial^® Iron, the innovative formulation behind the SiderAL^® product line, has been included in the latest World Health Organization (WHO) guidelines titled “Guidance on Implementing Patient Blood Management to Improve Global Blood Health Status.”

This document focuses on optimizing patient blood resource management to reduce the need for transfusions. It is the result of extensive collaboration among international experts from various multidisciplinary fields, all dedicated to improving patient outcomes, safety, and quality of care. As such, it also serves as a practical guide on iron deficiency and anemia, as well as the management of blood loss and bleeding disorders.

Notably, regarding iron deficiency in cardiovascular diseases and diabetes, Sucrosomial^® Iron is the only oral iron cited and acknowledged in the WHO Guidelines. This is a significant recognition of Sucrosomial^® Technology, the unique delivery system developed and patented by PharmaNutra, which protects micronutrient molecules such as iron, enhancing absorption and improving gastrointestinal tolerance.

This achievement is particularly impactful, considering that iron deficiency remains the most widespread nutritional deficiency worldwide. The WHO document highlights that anemia is a common condition among individuals with cardiovascular diseases and diabetes. It is estimated that at least 170 million people globally with these comorbidities also suffer from anemia.

Germano Tarantino, Chief Scientific Officer of PharmaNutra S.p.A., states: ““The reference to Sucrosomial^® Iron within the World Health Organisation Guidelines is an important recognition of the value of our patent, now of worldwide relevance, but also for the work carried out by our research and development department in recent years. This evidence gives us further impetus to continue to invest in research to further refine and improve Sucrosomial^® Technology, and to ensure increasingly effective solutions both as a means of preventing and counteracting iron deficiency, and as supplementation in all areas where this condition is one of the most frequent complications.”